Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PIK3CA mutation + ER positive

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

ER positive (199)

HR positive (184)

HR negative (25)

ER negative (13)

ER positive + PGR positive (12)

HR positive + HER-2 negative (5)

ER expression (3)

ER overexpression (3)

IRF8 overexpression + ER negative (3)

PIK3CA expression (3)

ER positive + HER-2 negative (2)

ER positive + PGR negative (2)

FGFR1 overexpression + HR positive (2)

HR negative + PD-L1 expression (2)

HR positive + ER overexpression (2)

HR positive + HER-2 underexpression (2)

AR positive + ER positive (1)

CETN2 overexpression + HR positive (1)

CETN2 overexpression + MLH3 overexpression + PCNA overexpression + HR positive (1)

CTSD positive + ER positive (1)

ER negative + HER-2 negative (1)

ER positive + CDK6 overexpression (1)

ER positive + PGR negative + HER-2 negative (1)

ER underexpression (1)

HDC overexpression + HR positive (1)

HER-2 underexpression + ER underexpression (1)

HR overexpression (1)

HR positive + AR positive (1)

HR positive + BRCA positive (1)

HR positive + CCNE1 overexpression (1)

HR positive + ERBB3 overexpression (1)

HR positive + ERBB3 underexpression (1)

HR positive + HER-2 positive (1)

HR positive + PD-L1 expression (1)

HR positive + PLK1 overexpression (1)

HR positive + TNFRSF11A overexpression (1)

MLH3 overexpression + HR positive (1)

NOTCH3 expression + ER positive + PGR positive (1)

PCNA overexpression + HR positive (1)

PD-L1 overexpression + ER positive (1)

RAD51 overexpression + HR positive (1)

RFC3 overexpression + ER positive (1)

TFF1 overexpression + ER positive (1)

TFF3 overexpression + ER positive (1)

TNFRSF1A overexpression + HR positive (1)

TYMS overexpression + HR positive (1)

PIK3CA overexpression (1)

BIN3 expression + ER positive (0)

CCNA2 expression + ER positive (0)

CCNB2 expression + ER positive (0)

CTDSP1 expression + ER positive (0)

EPRS1 expression + ER positive (0)

ER negative + HER-2 positive (0)

ER negative + PGR positive (0)

ER positive + HER-2 positive (0)

ER positive + PGR positive + HER-2 positive (0)

FOXD1 expression + ER positive (0)

FTO expression + ER positive (0)

HER-2 negative + AR positive + ER positive (0)

HER-2 negative + ER positive (0)

HR negative + HER-2 positive (0)

MIEN1 expression + ER negative + PR negative (0)

NCOR2 overexpression + ER positive (0)

RBPMS expression + ER positive (0)

SLBP expression + ER positive (0)

WSB2 expression + ER positive (0)

ER positive (199)

HR positive (184)

HR negative (25)

ER negative (13)

ER positive + PGR positive (12)

HR positive + HER-2 negative (5)

ER expression (3)

ER overexpression (3)

IRF8 overexpression + ER negative (3)

PIK3CA expression (3)

ER positive + HER-2 negative (2)

ER positive + PGR negative (2)

FGFR1 overexpression + HR positive (2)

HR negative + PD-L1 expression (2)

HR positive + ER overexpression (2)

HR positive + HER-2 underexpression (2)

AR positive + ER positive (1)

CETN2 overexpression + HR positive (1)

CETN2 overexpression + MLH3 overexpression + PCNA overexpression + HR positive (1)

CTSD positive + ER positive (1)

ER negative + HER-2 negative (1)

ER positive + CDK6 overexpression (1)

ER positive + PGR negative + HER-2 negative (1)

ER underexpression (1)

HDC overexpression + HR positive (1)

HER-2 underexpression + ER underexpression (1)

HR overexpression (1)

HR positive + AR positive (1)

HR positive + BRCA positive (1)

HR positive + CCNE1 overexpression (1)

HR positive + ERBB3 overexpression (1)

HR positive + ERBB3 underexpression (1)

HR positive + HER-2 positive (1)

HR positive + PD-L1 expression (1)

HR positive + PLK1 overexpression (1)

HR positive + TNFRSF11A overexpression (1)

MLH3 overexpression + HR positive (1)

NOTCH3 expression + ER positive + PGR positive (1)

PCNA overexpression + HR positive (1)

PD-L1 overexpression + ER positive (1)

RAD51 overexpression + HR positive (1)

RFC3 overexpression + ER positive (1)

TFF1 overexpression + ER positive (1)

TFF3 overexpression + ER positive (1)

TNFRSF1A overexpression + HR positive (1)

TYMS overexpression + HR positive (1)

PIK3CA overexpression (1)

BIN3 expression + ER positive (0)

CCNA2 expression + ER positive (0)

CCNB2 expression + ER positive (0)

CTDSP1 expression + ER positive (0)

EPRS1 expression + ER positive (0)

ER negative + HER-2 positive (0)

ER negative + PGR positive (0)

ER positive + HER-2 positive (0)

ER positive + PGR positive + HER-2 positive (0)

FOXD1 expression + ER positive (0)

FTO expression + ER positive (0)

HER-2 negative + AR positive + ER positive (0)

HER-2 negative + ER positive (0)

HR negative + HER-2 positive (0)

MIEN1 expression + ER negative + PR negative (0)

NCOR2 overexpression + ER positive (0)

RBPMS expression + ER positive (0)

SLBP expression + ER positive (0)

WSB2 expression + ER positive (0)

›

PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B	GDC-0032 Sensitive: B - Late Trials GDC-0032 Sensitive : B
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	alpelisib Sensitive: C3 – Early Trials alpelisib Sensitive : C3	alpelisib Sensitive: C3 – Early Trials alpelisib Sensitive : C3
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3	palbociclib + GDC-0032 Sensitive: C3 – Early Trials palbociclib + GDC-0032 Sensitive : C3
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	fulvestrant Sensitive: D – Preclinical fulvestrant Sensitive : D	fulvestrant Sensitive: D – Preclinical fulvestrant Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	everolimus Sensitive: D – Preclinical everolimus Sensitive : D	everolimus Sensitive: D – Preclinical everolimus Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + alpelisib Sensitive: D – Preclinical palbociclib + alpelisib Sensitive : D	palbociclib + alpelisib Sensitive: D – Preclinical palbociclib + alpelisib Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	alpelisib + ribociclib Sensitive: D – Preclinical alpelisib + ribociclib Sensitive : D	alpelisib + ribociclib Sensitive: D – Preclinical alpelisib + ribociclib Sensitive : D
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	STX-478 Sensitive: D – Preclinical STX-478 Sensitive : D	STX-478 Sensitive: D – Preclinical STX-478 Sensitive : D